We are pleased to announce that our abstract has been selected for an oral presentation at APASL 2024. The Asia-Pacific Association for the Study of Liver (APASL) Congress is an important event in the field of hepatology, bringing together experts from around the globe to discuss the latest advancements, research findings, and clinical insights.
Our presentation promises to contribute valuable insights to the conference program. We are honoured to have this platform to share our research and engage with fellow professionals in the field.
Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1
March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
